Pitch

Eligibility

  • At least one woman founder with an academic appointment at a research institution
  • Product concept no more than 4 years from IND or product launch
  • At least one presenter holds a pending or issued patent or copyright
  • No formal incorporation required. However, if a startup has been formed, the company should not have raised more than $1M USD
>> Pitch Application

2020 (Inaugural Pitchers)

Diagnostics & Medical Devices Pitchers

Reetuparna Das
University of Michigan
Startup: Sequal
Technology: Ultra-rapid molecular diagnosis of cancer

Melanie Joy
University of Colorado
Startup: Katharos, Inc.
Technology: Extracorporeal device for optimizing phosphate control in hemodialysis

Sunyoung Kim
Louisiana State UniversitySchool of Medicine & Health Sciences Center
Startup:Chosen Diagnostics Inc.
Technology:Biomarker panel to improve necrotizing enterocolitis diagnosis

Kacey Marra
University of Pittsburgh
Startup: AxoMax Technologies, Inc.
Technology: Biodegradable nerve guide

Sarah Vigmostad
The University of Iowa
Startup: SynderBio, Inc.
Technology: Novel, high-throughput cell separation
techniques for single cell sequencing and cancer diagnosis

Pamela Woodard
Washington University in St. Louis
Startup: GwynTech
Technology: AtheroBrite

Therapeutics Pitchers

Alexis Demonbreun
Northwestern University
Startup: Ikaika Therapeutics
Technology: Genetic modifiers of muscle disease
as therapeutic targets

Barbara Ehrlich
Yale University
Startup: Center Pharm
Technology: A new target for treatment of
Wolfram Syndrome

Yiping Han
Columbia University
Technology: Novel therapeutics to treat familial adenomatous polyposis (FAP)

Sandhya Kortagere
Drexel University
Technology: A disease modifying and neuroprotective agent to treat Parkinson’s disease

Martina Roos
University of California, Los Angeles
Startup: Sardona Therapeutics
Technology: Small molecules targeting RNA regulators in cancer stem cells

Judith Sebolt-Leopold
University of Michigan
Startup: Mekanistic Therapeutics
Technology: A first-in-class therapeutic targeting deregulation of EGFR and PI3K